Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs' Board met on May 30, 2025 and approved audited results for Q4 and FY ended March 31, 2025. The company reported no revenue from operations; its total income of Rs. 64.02 lakhs came entirely from other income (likely interest). Net loss for FY25 widened to Rs. 108.56 lakhs from Rs. 73.61 lakhs in FY24, while Q4 alone swung to a Rs. 39.36 lakh profit (aided by a one-time negative reclassification of other expenses). The balance sheet strengthened dramatically — cash jumped to Rs. 21.30 crore from Rs. 2.67 crore after a Rs. 21.80 crore preferential issue in Feb 2024, with no deviation in fund use reported. Borrowings fell sharply to Rs. 43.74 lakhs from Rs. 170.85 lakhs, but operating cash flow deteriorated sharply to negative Rs. 470.68 lakhs (vs. negative Rs. 20.85 lakhs). Auditor PP N & Company issued an unmodified opinion, and Anshu Chouhan & Associates was appointed as Secretarial Auditor for FY24-25.
Core operations remain inactive with zero operating revenue, losses are deepening, and operating cash burn has worsened sharply — the company's financial health is entirely propped up by the recent preferential issue. Shareholders should watch whether management deploys the large cash pile into a viable business plan, as continued losses with no revenue visibility is a concern.